Jose Morachis

Lynx Biosciences | Reimagining Translational Research with Patient-Centric Models Lynx Biosciences (LynxBio) is reshaping translational and reverse translational research by combining patient-derived cell models, microphysiological systems (MPS), and integrated multi-omic analyses to generate clinically meaningful insights—earlier and without reliance on animal models. Our platform supports high-content functional profiling of antibody and cell-based therapies in complex ex vivo co-cultures. These models preserve the native biology of the tumor and immune microenvironment, enabling more predictive, human-relevant data from the outset. As the field shifts toward more scalable, patient-centric approaches to drug development, LynxBio offers a solution built to meet this moment. We work across oncology and immunology indications to: • Profile therapeutic activity in ex vivo models • Integrate imaging, cytokine analysis, and transcriptomics from the same culture • Identify predictive biomarkers and stratify responders • Uncover resistance mechanisms and guide target refinement Our approach enables the resolution of responder and non-responder profiles, mechanistic biomarkers, and functional signatures from limited clinical material—accelerating the development of novel biologics and cell-engaging therapies. Whether you are advancing bispecific antibodies, cell engagers, or radiotherapeutics, LynxBio offers a plug-in, human-relevant platform to de-risk development, guide patient selection, and inform smarter, earlier decisions. Unlock deeper insight from fewer cells. Partner with LynxBio.

Notable is an AI-powered platform that helps startups and growing teams organize patents, agreements, and filings in one place. With automated deadline reminders and smart insights, we give you control of your most valuable asset—your intellectual property—so you can focus on building and scaling.

We fuel early stage life science startups that focus on R&D tools, platform technologies, and computational biology to solve todays roadblocks and allow for tomorrows discoveries and therapeutics to thrive. We aim to discover and support diverse science entrepreneurs with backgrounds in multi-omics, bioengineering, synthetic biology, and cell & gene therapies. Currently fundraising for Fund I and making select investments. We welcome discussions with entrepreneurial scientists ready to spin something out of academia or out of the garage.

Lynx Biosciences | Reimagining Translational Research with Patient-Centric Models Lynx Biosciences (LynxBio) is reshaping translational and reverse translational research by combining patient-derived cell models, microphysiological systems (MPS), and integrated multi-omic analyses to generate clinically meaningful insights—earlier and without reliance on animal models. Our platform supports high-content functional profiling of antibody and cell-based therapies in complex ex vivo co-cultures. These models preserve the native biology of the tumor and immune microenvironment, enabling more predictive, human-relevant data from the outset. As the field shifts toward more scalable, patient-centric approaches to drug development, LynxBio offers a solution built to meet this moment. We work across oncology and immunology indications to: • Profile therapeutic activity in ex vivo models • Integrate imaging, cytokine analysis, and transcriptomics from the same culture • Identify predictive biomarkers and stratify responders • Uncover resistance mechanisms and guide target refinement Our approach enables the resolution of responder and non-responder profiles, mechanistic biomarkers, and functional signatures from limited clinical material—accelerating the development of novel biologics and cell-engaging therapies. Whether you are advancing bispecific antibodies, cell engagers, or radiotherapeutics, LynxBio offers a plug-in, human-relevant platform to de-risk development, guide patient selection, and inform smarter, earlier decisions. Unlock deeper insight from fewer cells. Partner with LynxBio.

Our mission is to improve the way we grow cells for stem cell R&D and cultured meat production. We care about making a positive impact in reducing animal dependency for lab reagents and eventually for food as well. Defined Bios journey starts with transforming stem cell growth medium by understanding the most critical stem cell research needs - cell growth quality, cost, and ease of use. To meet the growing demands of various customer segments, we realized that we would have to optimize all of the fundamental ingredients of defined, animal free growth media: growth factors, proteins, buffers, and growth/differentiation analysis. We have developed innovative reagents across traditional recipes, leveraging published and optimized recipes from leaders in the field. The result is exceptional reagents, media, and protocols that will materially improve quality and reduce the cost of growing stem cells and iPSC derived cells.

NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, by ensuring high cell viability required to advance cell-based research. We develop and deliver microfluidic based solutions that are affordable, compact, and easy-to-use. Our expanding portfolio of instruments and consumables enable biomedical scientists to analyze and sort cells required for drug discovery, single cell-omics, cloning, antibody discovery, and basic research.